miR520c blocks EMT progression of human breast cancer cells by repressing STAT3

Wang,Nian; Wei,Lan; Huang,Yunxiu; Wu,Yang; Su,Min; Pang,Xueli; Wang,Nian; Ji,Feihu; Zhong,Changli; Chen,Tingmei; Li,Bing

doi:10.3892/or.2017.5393

miR520c blocks EMT progression of human breast cancer cells by repressing STAT3

Authors:
- Nian Wang
- Lan Wei
- Yunxiu Huang
- Yang Wu
- Min Su
- Xueli Pang
- Feihu Ji
- Changli Zhong
- Tingmei Chen
- Bing Li
View Affiliations

Affiliations: Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China
Published online on: January 19, 2017 https://doi.org/10.3892/or.2017.5393
Pages: 1537-1544

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most malignant diseases world-wide and it ranks the first among female cancers. Masses of intrinsic and extrinsic factors, especially the inflammatory factors can lead to breast cancer. Aberrant activation and accumulation of key molecules can lead to inflammation associated carcinogenesis. The signal transducers and activators of transcription 3 (STAT3) is one of them. Therefore, to evaluate the novel molecular mechanisms, STAT3 has become our focus for breast cancer targeted therapy. At present, many tumor suppressing microRNAs have been validated, and are the highlights in research on microRNAs. Thus, we predicted microRNAs which could putatively regulate STAT3 through databases and selected six to screen with Dual-luciferase assay. The result hinted that miR520c could bind with STAT3 3'UTR. We mutated the seed sequence of miR520c on STAT3 3'UTR, which illustrated a reverse effect compared with wild-type of STAT3 3'UTR. Subsequently, STAT3, p-STAT3 and miR520c were assessed in three different grades of breast cancer cells, with the degree of malignancy, we found an escalating trend of STAT3 and p-STAT3, on the contrary, a downward trend of miR520c. We observed STAT3 was deactivated by miR520c. Epithelial to mesenchymal transition (EMT) is a fatal transfer of cancer progression. To find out whether the downregulation of STAT3 can repress breast cancer motility and invasion ability, we detected EMT markers. The result implied a suppression effect on EMT. We overexpressed STAT3 to conduct rescue experiments, the result showed a recovery of STAT3 and EMT characteristics. Cell motility and invasion property were regained as well. In the study, we elucidated miR520c could inhibit breast cancer EMT by targeting STAT3. It can enrich the mechanism of breast cancer and may lay the foundation for breast cancer targeted treatment.

View Figures

View References

1	De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D and Plummer M: Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol. 13:607–615. 2012. View Article : Google Scholar : PubMed/NCBI
2	Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
3	Yaacoub K, Pedeux R, Tarte K and Guillaudeux T: Role of the tumor microenvironment in regulating apoptosis and cancer progression. Cancer Lett. 378:150–159. 2016. View Article : Google Scholar : PubMed/NCBI
4	Ma YF, Ren Y, Wu CJ, Zhao XH, Xu H, Wu DZ, Xu J, Zhang XL and Ji Y: Interleukin (IL)-24 transforms the tumor microenvironment and induces anticancer immunity in a murine model of colon cancer. Mol Immunol. 75:11–20. 2016. View Article : Google Scholar : PubMed/NCBI
5	Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg GD and Gajewski TF: Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 4:563–568. 2016. View Article : Google Scholar : PubMed/NCBI
6	Fernandez-Garcia B, Eiró N, Miranda MA, Cid S, González LO, Domínguez F and Vizoso FJ: Prognostic significance of inflammatory factors expression by stroma from breast carcinomas. Carcinogenesis. 37:768–776. 2016. View Article : Google Scholar : PubMed/NCBI
7	Dieci MV, Griguolo G, Miglietta F and Guarneri V: The immune system and hormone-receptor positive breast cancer: Is it really a dead end? Cancer Treat Rev. 46:9–19. 2016. View Article : Google Scholar : PubMed/NCBI
8	Griesinger AM, Josephson RJ, Donson AM, Levy JM Mulcahy, Amani V, Birks DK, Hoffman LM, Furtek SL, Reigan P, Handler MH, et al: Interleukin-6/STAT3 pathway signaling drives an inflammatory phenotype in group A ependymoma. Cancer Immunol Res. 3:1165–1174. 2015. View Article : Google Scholar : PubMed/NCBI
9	Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr.: Stat3 as an oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
10	Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
11	Garcia R and Jove R: Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci. 5:79–85. 1998. View Article : Google Scholar : PubMed/NCBI
12	Meltzer PS: Cancer genomics: Small RNAs with big impacts. Nature. 435:745–746. 2005. View Article : Google Scholar : PubMed/NCBI
13	Benhamed M, Herbig U, Ye T, Dejean A and Bischof O: Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells. Nat Cell Biol. 14:266–275. 2012. View Article : Google Scholar : PubMed/NCBI
14	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P and Calin GA: Epigenetic regulation of microRNAs in cancer: An integrated review of literature. Mutat Res. 717:77–84. 2011. View Article : Google Scholar : PubMed/NCBI
16	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
17	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
18	Ferdin J, Kunej T and Calin GA: Non-coding RNAs: Identification of cancer-associated microRNAs by gene profiling. Technol Cancer Res Treat. 9:123–138. 2010. View Article : Google Scholar : PubMed/NCBI
19	Fabbri M, Ivan M, Cimmino A, Negrini M and Calin GA: Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 7:1009–1019. 2007. View Article : Google Scholar : PubMed/NCBI
20	Yang YK, Xi WY, Xi RX, Li JY, Li Q and Gao YE: MicroRNA-494 promotes cervical cancer proliferation through the regulation of PTEN. Oncol Rep. 33:2393–2401. 2015.PubMed/NCBI
21	Libório-Kimura TN, Jung HM and Chan EK: miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer. Oral Oncol. 51:151–157. 2015. View Article : Google Scholar : PubMed/NCBI
22	Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin O and Wiemann S: MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol. 233:368–379. 2014. View Article : Google Scholar : PubMed/NCBI
23	Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM and Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 30:1082–1097. 2011. View Article : Google Scholar : PubMed/NCBI
24	Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Gückel B, Fehm T, Schneeweiss A, et al: MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene. 31:4150–4163. 2012. View Article : Google Scholar : PubMed/NCBI
25	Liu LY, Chang LY, Kuo WH, Hwa HL, Lin YS, Jeng MH, Roth DA, Chang KJ and Hsieh FJ: Correction to: Prognostic features of signal transducer and activator of transcription 3 in an ER(+) breast cancer model system. Cancer Inform. 13:125–129. 2014.PubMed/NCBI
26	Im CN, Yun HH, Song B, Youn DY, Cui MN, Kim HS, Park GS and Lee JH: BIS-mediated STAT3 stabilization regulates glioblastoma stem cell-like phenotypes. Oncotarget. 7:35056–35070. 2016.PubMed/NCBI
27	Yang H, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y and Kroemer G: Improvement of immunogenic chemotherapy by STAT3 inhibition. OncoImmunology. 5:e10780612015. View Article : Google Scholar : PubMed/NCBI
28	Zhang JL, Liu XZ, Wang PY, Chen GW, Jiang Y, Qiao SK, Zhu J, Wang X, Pan YS and Liu YC: Targeting HCCR expression resensitizes gastric cancer cells to chemotherapy via down-regulating the activation of STAT3. Sci Rep. 6:241962016. View Article : Google Scholar : PubMed/NCBI
29	Wang J, Zhang N, Qu H, You G, Yuan J, Chen C, Li W and Pan F: Inhibitory effect of STAT3 gene combined with CDDP on growth of human Wilms tumour SK-NEP-1 cells. Biosci Rep. 36:e003422016. View Article : Google Scholar : PubMed/NCBI
30	Su R, Dong L, Zou D, Zhao H, Ren Y, Li F, Yi P, Li L, Zhu Y, Ma Y, et al: microRNA-23a, −27a and −24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. Oncogene. 35:6001–6014. 2016. View Article : Google Scholar : PubMed/NCBI
31	Li W, Huang H, Su J, Ji X, Zhang X, Zhang Z and Wang H: miR-124 acts as a tumor suppressor in glioblastoma via the inhibition of signal transducer and activator of transcription 3. Mol Neurobiol. Mar 18–2016.(Epub ahead of print).
32	Fan Z, Cui H, Yu H, Ji Q, Kang L, Han B, Wang J, Dong Q, Li Y, Yan Z, et al: MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression. Oncogenesis. 5:e1972016. View Article : Google Scholar : PubMed/NCBI
33	Fomeshi MR, Ebrahimi M, Mowla SJ, Khosravani P, Firouzi J and Khayatzadeh H: Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells. Cell Mol Biol Lett. 20:448–465. 2015. View Article : Google Scholar : PubMed/NCBI
34	Mazan-Mamczarz K, Zhao XF, Dai B, Steinhardt JJ, Peroutka RJ, Berk KL, Landon AL, Sadowska M, Zhang Y, Lehrmann E, et al: Down-regulation of eIF4GII by miR-520c-3p represses diffuse large B cell lymphoma development. PLoS Genet. 10:e10041052014. View Article : Google Scholar : PubMed/NCBI
35	Lu S, Zhu Q, Zhang Y, Song W, Wilson MJ and Liu P: Dual-Functions of miR-373 and miR-520c by differently regulating the activities of MMP2 and MMP9. J Cell Physiol. 230:1862–1870. 2015. View Article : Google Scholar : PubMed/NCBI